A citation-based method for searching scientific literature

Thomas F Dejgaard, Signe Schmidt, Christian S Frandsen, Dorte Vistisen, Sten Madsbad, Henrik U Andersen, Kirsten Nørgaard. Diabetes Obes Metab 2020
Times Cited: 5







List of co-cited articles
28 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
597
60

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
697
60

Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms.
Karen D Corbin, Kimberly A Driscoll, Richard E Pratley, Steven R Smith, David M Maahs, Elizabeth J Mayer-Davis. Endocr Rev 2018
56
40

Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents.
Christine Ferrara-Cook, Susan Michelle Geyer, Carmella Evans-Molina, Ingrid M Libman, Dorothy J Becker, Stephen E Gitelman, Maria Jose Redondo. Diabetes Care 2020
7
40

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
768
40

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Bernard Zinman, Vanita R Aroda, John B Buse, Bertrand Cariou, Stewart B Harris, Søren Tetens Hoff, Karen Boje Pedersen, Mads Jeppe Tarp-Johansen, Eiichi Araki. Diabetes Care 2019
52
40

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Thomas R Pieber, Bruce Bode, Ann Mertens, Young Min Cho, Erik Christiansen, Christin L Hertz, Signe O R Wallenstein, John B Buse. Lancet Diabetes Endocrinol 2019
72
40

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
570
40

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
335
40

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
40

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Christian S Frandsen, Julie L Forman, Nicolai J Wewer Albrechtsen, Jens J Holst, Ulrik Pedersen-Bjergaard, Sten Madsbad,[...]. Lancet Diabetes Endocrinol 2020
11
40

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
40

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
916
40

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
40

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
200
40

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Richard Pratley, Aslam Amod, Søren Tetens Hoff, Takashi Kadowaki, Ildiko Lingvay, Michael Nauck, Karen Boje Pedersen, Trine Saugstrup, Juris J Meier. Lancet 2019
128
40

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding. Lancet 2018
167
40

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Kathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, José G González González, Charles Atisso, Whitney Sealls, Jessie L Fahrbach. Lancet 2014
270
40

Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
440
40

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
344
40

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
72
40


Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
100
40


A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
185
40

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
120
40

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
96
40

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
71
40

Evolution of body mass index in children with type 1 diabetes mellitus.
Marijke De Keukelaere, Steffen Fieuws, Nele Reynaert, Eva Vandoorne, Kristel Vande Kerckhove, Willeke Asscherickx, Kristina Casteels. Eur J Pediatr 2018
14
20

High prevalence of diabetes-specific autoimmunity in first-degree relatives of Sardinian patients with type 1 diabetes.
M Incani, C Serafini, C Satta, L Perra, F Scano, P Frongia, R Ricciardi, C Ripoli, M Soro, A Strazzera,[...]. Diabetes Metab Res Rev 2017
6
20

Evidence of diabetes-specific autoimmunity in obese subjects with normal glucose tolerance.
Claudio Tiberti, Simona Zampetti, Danila Capoccia, Giuseppe Campagna, Federica Lucantoni, Emanuela Anastasi, Lucia Pallotta, Francesca Panimolle, Gaetano Leto, Andrea Lenzi,[...]. Diabetes Metab Res Rev 2018
5
20

The distribution of HLA class II susceptible/protective haplotypes could partially explain the low incidence of type 1 diabetes in continental Italy (Lazio region).
A Petrone, T L Bugawan, C A Mesturino, L Nisticò, A Galgani, G Giorgi, I Cascino, H A Erlich, U Di Mario, R Buzzetti. Tissue Antigens 2001
41
20

Temporal profiling of cytokine-induced genes in pancreatic β-cells by meta-analysis and network inference.
Miguel Lopes, Burak Kutlu, Michela Miani, Claus H Bang-Berthelsen, Joachim Størling, Flemming Pociot, Nathan Goodman, Lee Hood, Nils Welsh, Gianluca Bontempi,[...]. Genomics 2014
35
20

Type 1 diabetes in young adulthood.
Maureen Monaghan, Vicki Helgeson, Deborah Wiebe. Curr Diabetes Rev 2015
64
20

NF-κB and STAT1 control CXCL1 and CXCL2 gene transcription.
Susan J Burke, Danhong Lu, Tim E Sparer, Thomas Masi, Matthew R Goff, Michael D Karlstad, J Jason Collier. Am J Physiol Endocrinol Metab 2014
68
20


A new expression of diabetes: double diabetes.
Paolo Pozzilli, Raffaella Buzzetti. Trends Endocrinol Metab 2007
53
20

Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study.
Xin Wang, You Li, Katherine L O'Brien, Shabir A Madhi, Marc-Alain Widdowson, Peter Byass, Saad B Omer, Qalab Abbas, Asad Ali, Alberta Amu,[...]. Lancet Glob Health 2020
49
20

Pancreatic β-Cell production of CXCR3 ligands precedes diabetes onset.
Susan J Burke, Michael D Karlstad, Adrianna E Eder, Kellie M Regal, Danhong Lu, David H Burk, J Jason Collier. Biofactors 2016
18
20

Environmental risk factors for type 1 diabetes.
Marian Rewers, Johnny Ludvigsson. Lancet 2016
239
20

Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications: A position statement of the Italian Society of Diabetology.
R Buzzetti, S Prudente, M Copetti, M Dauriz, S Zampetti, M Garofolo, G Penno, V Trischitta. Nutr Metab Cardiovasc Dis 2017
8
20

Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis.
David A McAllister, Li Liu, Ting Shi, Yue Chu, Craig Reed, John Burrows, Davies Adeloye, Igor Rudan, Robert E Black, Harry Campbell,[...]. Lancet Glob Health 2019
126
20

Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes.
Raffaella Buzzetti, Marialuisa Spoletini, Simona Zampetti, Giuseppe Campagna, Lidia Marandola, Francesca Panimolle, Francesco Dotta, Claudio Tiberti. Diabetes Care 2015
17
20

Overweight and obesity in type 1 diabetes equal those of the general population.
Paul Fellinger, David Fuchs, Peter Wolf, Georg Heinze, Anton Luger, Michael Krebs, Yvonne Winhofer. Wien Klin Wochenschr 2019
14
20

Combination immunotherapies for type 1 diabetes mellitus.
Paolo Pozzilli, Ernesto Maddaloni, Raffaella Buzzetti. Nat Rev Endocrinol 2015
41
20

Trends in high-risk HLA susceptibility genes among Colorado youth with type 1 diabetes.
Kendra Vehik, Richard F Hamman, Dennis Lezotte, Jill M Norris, Georgeanna J Klingensmith, Marian Rewers, Dana Dabelea. Diabetes Care 2008
51
20



Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?
Christine Therese Ferrara, Susan Michelle Geyer, Yuk-Fun Liu, Carmella Evans-Molina, Ingrid M Libman, Rachel Besser, Dorothy J Becker, Henry Rodriguez, Antoinette Moran, Stephen E Gitelman,[...]. Diabetes Care 2017
38
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.